Advertisement

Journal of Neuroimmune Pharmacology

, Volume 9, Issue 2, pp 182–194 | Cite as

Neurotrophin Strategies for Neuroprotection: Are They Sufficient?

  • Joseph P. SteinerEmail author
  • Avindra Nath
INVITED REVIEW

Abstract

As people are living longer, the prevalance of neurodegenerative diseases continues to rise resulting in huge socio-economic consequences. Despite major advancements in studying the pathophysiology of these diseases and a large number of clinical trials currently there is no effective treatment for these illnesses. All neuroprotective strategies have either failed or have shown only a minimal effect. There has been a major shift in recent years exploring the potential of neuroregenerative approaches. While the concept of using neurotropins for therapeutic purposes has been in existence for many years, new modes of delivery and expression of this family of molecules makes this approach now feasilble. Further neurotropin mimetics and receptor agonists are also being developed. The use of small molecules to induce the expression of neurotropins including repurposing of FDA approved drugs for this approach is another strategy being pursued. In the review we examine these new developments and discuss the potential for such approaches in the context of the pathophysiology of neurodegenerative diseases.

Keywords

Degeneration Neurons Neurotrophin Neuroprotection 

References

  1. Adlard PA, Perreau VM, Engesser-Cesar C, Cotman CW (2004) The timecourse of induction of brain-derived neurotrophic factor mRNA and protein in the rat hippocampus following voluntary exercise. Neurosci Lett 363:43–48PubMedGoogle Scholar
  2. Adlard PA, Perreau VM, Cotman CW (2005) The exercise-induced expression of BDNF within the hippocampus varies across life-span. Neurobiol Aging 26:511–520PubMedGoogle Scholar
  3. Alcala-Barraza SR, Lee MS, Hanson LR, McDonald AA, Frey WH 2nd, McLoon LK (2010) Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS. J Drug Target 18:179–190PubMedCentralPubMedGoogle Scholar
  4. Allen SJ, Watson JJ, Shoemark DK, Barua NU, Patel NK (2013) GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacol Ther 138:155–175PubMedGoogle Scholar
  5. Aloe L, Rocco ML, Bianchi P, Manni L (2012) Nerve growth factor: from the early discoveries to the potential clinical use. J Transl Med 10:239PubMedCentralPubMedGoogle Scholar
  6. Angelucci F, Croce N, Spalletta G, Dinallo V, Gravina P, Bossu P, Federici G, Caltagirone C, Bernardini S (2011) Paroxetine rapidly modulates the expression of brain-derived neurotrophic factor mRNA and protein in a human glioblastoma-astrocytoma cell line. Pharmacology 87:5–10PubMedGoogle Scholar
  7. Ankeny DP, McTigue DM, Guan Z, Yan Q, Kinstler O, Stokes BT, Jakeman LB (2001) Pegylated brain-derived neurotrophic factor shows improved distribution into the spinal cord and stimulates locomotor activity and morphological changes after injury. Exp Neurol 170:85–100PubMedGoogle Scholar
  8. Apostol BL, Simmons DA, Zuccato C, Illes K, Pallos J, Casale M, Conforti P, Ramos C, Roarke M, Kathuria S, Cattaneo E, Marsh JL, Thompson LM (2008) CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice. Mol Cell Neurosci 39:8–20PubMedGoogle Scholar
  9. Appel SH (1981) A unifying hypothesis for the cause of amyotrophic lateral sclerosis, parkinsonism, and Alzheimer disease. Ann Neurol 10:499–505PubMedGoogle Scholar
  10. Autio H, Matlik K, Rantamaki T, Lindemann L, Hoener MC, Chao M, Arumae U, Castren E (2011) Acetylcholinesterase inhibitors rapidly activate Trk neurotrophin receptors in the mouse hippocampus. Neuropharmacology 61:1291–1296PubMedCentralPubMedGoogle Scholar
  11. Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, Kavalali ET, Monteggia LM (2011) NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475:91–95PubMedCentralPubMedGoogle Scholar
  12. Avramovich-Tirosh Y, Bar-Am O, Amit T, Youdim MB, Weinreb O (2010) Up-regulation of hypoxia-inducible factor (HIF)-1alpha and HIF-target genes in cortical neurons by the novel multifunctional iron chelator anti-Alzheimer drug, M30. Curr Alzheimer Res 7:300–306PubMedGoogle Scholar
  13. Bachis A, Major EO, Mocchetti I (2003) Brain-derived neurotrophic factor inhibits human immunodeficiency virus-1/gp120-mediated cerebellar granule cell death by preventing gp120 internalization. J Neurosci Off J Soc Neurosci 23:5715–5722Google Scholar
  14. Bachis A, Avdoshina V, Zecca L, Parsadanian M, Mocchetti I (2012) Human immunodeficiency virus type 1 alters brain-derived neurotrophic factor processing in neurons. J Neurosci Off J Soc Neurosci 32:9477–9484Google Scholar
  15. Bai O, Chlan-Fourney J, Bowen R, Keegan D, Li XM (2003) Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J Neurosci Res 71:127–131PubMedGoogle Scholar
  16. Bekinschtein P, Cammarota M, Katche C, Slipczuk L, Rossato JI, Goldin A, Izquierdo I, Medina JH (2008) BDNF is essential to promote persistence of long-term memory storage. Proc Natl Acad Sci U S A 105:2711–2716PubMedCentralPubMedGoogle Scholar
  17. Bellizzi MJ, Lu SM, Masliah E, Gelbard HA (2005) Synaptic activity becomes excitotoxic in neurons exposed to elevated levels of platelet-activating factor. J Clin Investig 115:3185–3192PubMedCentralPubMedGoogle Scholar
  18. Berkemeier LR, Winslow JW, Kaplan DR, Nikolics K, Goeddel DV, Rosenthal A (1991) Neurotrophin-5: a novel neurotrophic factor that activates trk and trkB. Neuron 7:857–866PubMedGoogle Scholar
  19. Bertram JP, Rauch MF, Chang K, Lavik EB (2010) Using polymer chemistry to modulate the delivery of neurotrophic factors from degradable microspheres: delivery of BDNF. Pharm Res 27:82–91PubMedGoogle Scholar
  20. Blochl A, Blochl R (2007) A cell-biological model of p75NTR signaling. J Neurochem 102:289–305PubMedGoogle Scholar
  21. Blurton-Jones M, Kitazawa M, Martinez-Coria H, Castello NA, Muller FJ, Loring JF, Yamasaki TR, Poon WW, Green KN, LaFerla FM (2009) Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci U S A 106:13594–13599PubMedCentralPubMedGoogle Scholar
  22. Borrell-Pages M, Canals JM, Cordelieres FP, Parker JA, Pineda JR, Grange G, Bryson EA, Guillermier M, Hirsch E, Hantraye P, Cheetham ME, Neri C, Alberch J, Brouillet E, Saudou F, Humbert S (2006) Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J Clin Investig 116:1410–1424PubMedCentralPubMedGoogle Scholar
  23. Calabrese F, Molteni R, Maj PF, Cattaneo A, Gennarelli M, Racagni G, Riva MA (2007) Chronic duloxetine treatment induces specific changes in the expression of BDNF transcripts and in the subcellular localization of the neurotrophin protein. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 32:2351–2359Google Scholar
  24. Cardenas-Aguayo Mdel C, Kazim SF, Grundke-Iqbal I, Iqbal K (2013) Neurogenic and neurotrophic effects of BDNF peptides in mouse hippocampal primary neuronal cell cultures. PloS one 8:e53596PubMedGoogle Scholar
  25. Cattaneo A, Bocchio-Chiavetto L, Zanardini R, Milanesi E, Placentino A, Gennarelli M (2010) Reduced peripheral brain-derived neurotrophic factor mRNA levels are normalized by antidepressant treatment. Int J Neuropsychopharmacol 13:103–108PubMedGoogle Scholar
  26. Chang YC, Rapoport SI, Rao JS (2009) Chronic administration of mood stabilizers upregulates BDNF and bcl-2 expression levels in rat frontal cortex. Neurochem Res 34:536–541PubMedCentralPubMedGoogle Scholar
  27. Chao MV (1994) The p75 neurotrophin receptor. J Neurobiol 25:1373–1385PubMedGoogle Scholar
  28. Chao MV, Hempstead BL (1995) p75 and Trk: a two-receptor system. Trends Neurosci 18:321–326PubMedGoogle Scholar
  29. Chao MV, Rajagopal R, Lee FS (2006) Neurotrophin signalling in health and disease. Clin Sci (Lond) 110:167–173Google Scholar
  30. Chen PS, Peng GS, Li G, Yang S, Wu X, Wang CC, Wilson B, Lu RB, Gean PW, Chuang DM, Hong JS (2006) Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol Psychiatry 11:1116–1125PubMedGoogle Scholar
  31. Chiu CT, Wang Z, Hunsberger JG, Chuang DM (2013) Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacol Rev 65:105–142PubMedCentralPubMedGoogle Scholar
  32. Cho HS, Kim S, Lee SY, Park JA, Kim SJ, Chun HS (2008) Protective effect of the green tea component, L-theanine on environmental toxins-induced neuronal cell death. Neurotoxicology 29:656–662PubMedGoogle Scholar
  33. Cohen S, Levi-Montalcini R, Hamburger V (1954) A nerve growth-stimulating factor isolated from sarcom as 37 and 180. Proc Natl Acad Sci U S A 40:1014–1018PubMedCentralPubMedGoogle Scholar
  34. Conforti P, Ramos C, Apostol BL, Simmons DA, Nguyen HP, Riess O, Thompson LM, Zuccato C, Cattaneo E (2008) Blood level of brain-derived neurotrophic factor mRNA is progressively reduced in rodent models of Huntington’s disease: restoration by the neuroprotective compound CEP-1347. Mol Cell Neurosci 39:1–7PubMedGoogle Scholar
  35. Cooke JD, Grover LM, Spangler PR (2009) Venlafaxine treatment stimulates expression of brain-derived neurotrophic factor protein in frontal cortex and inhibits long-term potentiation in hippocampus. Neuroscience 162:1411–1419PubMedGoogle Scholar
  36. Coppell AL, Pei Q, Zetterstrom TS (2003) Bi-phasic change in BDNF gene expression following antidepressant drug treatment. Neuropharmacology 44:903–910PubMedGoogle Scholar
  37. Czubak A, Nowakowska E, Kus K, Burda K, Metelska J, Baer-Dubowska W, Cichocki M (2009) Influences of chronic venlafaxine, olanzapine and nicotine on the hippocampal and cortical concentrations of brain-derived neurotrophic factor (BDNF). Pharmacol Reports 61:1017–1023Google Scholar
  38. Deogracias R, Yazdani M, Dekkers MP, Guy J, Ionescu MC, Vogt KE, Barde YA (2012) Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome. Proc Natl Acad Sci U S A 109:14230–14235PubMedCentralPubMedGoogle Scholar
  39. Doi Y, Takeuchi H, Horiuchi H, Hanyu T, Kawanokuchi J, Jin S, Parajuli B, Sonobe Y, Mizuno T, Suzumura A (2013) Fingolimod phosphate attenuates oligomeric amyloid beta-induced neurotoxicity via increased brain-derived neurotrophic factor expression in neurons. PloS One 8:e61988PubMedCentralPubMedGoogle Scholar
  40. Du F, Li R, Huang Y, Li X, Le W (2005) Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons. Eur J Neurosci 22:2422–2430PubMedGoogle Scholar
  41. Duan W, Guo Z, Jiang H, Ware M, Li XJ, Mattson MP (2003) Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice. Proc Natl Acad Sci U S A 100:2911–2916PubMedCentralPubMedGoogle Scholar
  42. Dwivedi Y, Rizavi HS, Pandey GN (2006) Antidepressants reverse corticosterone-mediated decrease in brain-derived neurotrophic factor expression: differential regulation of specific exons by antidepressants and corticosterone. Neuroscience 139:1017–1029PubMedCentralPubMedGoogle Scholar
  43. Ellis R, Langford D, Masliah E (2007) HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurosci 8:33–44PubMedGoogle Scholar
  44. Everall IP, Heaton RK, Marcotte TD, Ellis RJ, McCutchan JA, Atkinson JH, Grant I, Mallory M, Masliah E (1999) Cortical synaptic density is reduced in mild to moderate human immunodeficiency virus neurocognitive disorder. HNRC Group. HIV Neurobehavioral Research Center. Brain Pathol 9:209–217PubMedGoogle Scholar
  45. Fletcher JM, Hughes RA (2006) Novel monocyclic and bicyclic loop mimetics of brain-derived neurotrophic factor. J Pept Sci Off Publ Eur Pept Soc 12:515–524Google Scholar
  46. Fletcher JM, Hughes RA (2009) Modified low molecular weight cyclic peptides as mimetics of BDNF with improved potency, proteolytic stability and transmembrane passage in vitro. Bioorg Med Chem 17:2695–2702PubMedGoogle Scholar
  47. Fletcher JM, Morton CJ, Zwar RA, Murray SS, O’Leary PD, Hughes RA (2008) Design of a conformationally defined and proteolytically stable circular mimetic of brain-derived neurotrophic factor. J Biol Chem 283:33375–33383PubMedCentralPubMedGoogle Scholar
  48. Francis BM, Yang J, Hajderi E, Brown ME, Michalski B, McLaurin J, Fahnestock M, Mount HT (2012) Reduced tissue levels of noradrenaline are associated with behavioral phenotypes of the TgCRND8 mouse model of Alzheimer’s disease. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 37:1934–1944Google Scholar
  49. Frim DM, Uhler TA, Galpern WR, Beal MF, Breakefield XO, Isacson O (1994) Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc Natl Acad Sci U S A 91:5104–5108PubMedCentralPubMedGoogle Scholar
  50. Fujimaki K, Morinobu S, Duman RS (2000) Administration of a cAMP phosphodiesterase 4 inhibitor enhances antidepressant-induction of BDNF mRNA in rat hippocampus. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 22:42–51Google Scholar
  51. Géral C, Angelova A, Lesieur S (2013) From molecular to nanotechnology strategies for delivery of neurotrophins: emphasis on Brain-Derived Neurotrophic Factor (BDNF). Pharmaceutics 5:127–167PubMedCentralPubMedGoogle Scholar
  52. Gharami K, Xie Y, An JJ, Tonegawa S, Xu B (2008) Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington’s disease phenotypes in mice. J Neurochem 105:369–379PubMedCentralPubMedGoogle Scholar
  53. Gil-Bea FJ, Solas M, Mateos L, Winblad B, Ramirez MJ, Cedazo-Minguez A (2011) Cholinergic hypofunction impairs memory acquisition possibly through hippocampal Arc and BDNF downregulation. Hippocampus 21:999–1009PubMedGoogle Scholar
  54. Giralt A, Friedman HC, Caneda-Ferron B, Urban N, Moreno E, Rubio N, Blanco J, Peterson A, Canals JM, Alberch J (2010) BDNF regulation under GFAP promoter provides engineered astrocytes as a new approach for long-term protection in Huntington’s disease. Gene Ther 17:1294–1308PubMedGoogle Scholar
  55. Group TBS (1999) A controlled trial of recombinant methionyl BDNF in ALS: The BDNF Study Group (Phase III). Neurology 52:1427–1433Google Scholar
  56. Gruss HJ, Dower SK (1995) The TNF ligand superfamily and its relevance for human diseases. Cytokines Mol Ther 1:75–105PubMedGoogle Scholar
  57. Han Q, Sun W, Lin H, Zhao W, Gao Y, Zhao Y, Chen B, Xiao Z, Hu W, Li Y, Yang B, Dai J (2009) Linear ordered collagen scaffolds loaded with collagen-binding brain-derived neurotrophic factor improve the recovery of spinal cord injury in rats. Tissue Eng Part A 15:2927–2935PubMedGoogle Scholar
  58. Hashimoto R, Takei N, Shimazu K, Christ L, Lu B, Chuang DM (2002) Lithium induces brain-derived neurotrophic factor and activates TrkB in rodent cortical neurons: an essential step for neuroprotection against glutamate excitotoxicity. Neuropharmacology 43:1173–1179PubMedGoogle Scholar
  59. Hoshaw BA, Malberg JE, Lucki I (2005) Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects. Brain Res 1037:204–208PubMedGoogle Scholar
  60. Hou Y, Aboukhatwa MA, Lei DL, Manaye K, Khan I, Luo Y (2010) Anti-depressant natural flavonols modulate BDNF and beta amyloid in neurons and hippocampus of double TgAD mice. Neuropharmacology 58:911–920PubMedCentralPubMedGoogle Scholar
  61. Hutchinson AJ, Chou CL, Israel DD, Xu W, Regan JW (2009) Activation of EP2 prostanoid receptors in human glial cell lines stimulates the secretion of BDNF. Neurochem Int 54:439–446PubMedCentralPubMedGoogle Scholar
  62. Ihara D, Fukuchi M, Honma D, Takasaki I, Ishikawa M, Tabuchi A, Tsuda M (2012) Deltamethrin, a type II pyrethroid insecticide, has neurotrophic effects on neurons with continuous activation of the Bdnf promoter. Neuropharmacology 62:1091–1098PubMedGoogle Scholar
  63. Ikenouchi-Sugita A, Toyohira Y, Yoshimura R, Ueno S, Tsutsui M, Nakamura J, Yanagihara N (2009) Opposite effects of milnacipran, a serotonin norepinephrine reuptake inhibitor, on the levels of nitric oxide and brain-derived neurotrophic factor in mouse brain cortex. Naunyn-Schmiedeberg’s Arch Pharmacol 380:479–486Google Scholar
  64. Imamura L, Yasuda M, Kuramitsu K, Hara D, Tabuchi A, Tsuda M (2006) Deltamethrin, a pyrethroid insecticide, is a potent inducer for the activity-dependent gene expression of brain-derived neurotrophic factor in neurons. J Pharmacol Exp Ther 316:136–143PubMedGoogle Scholar
  65. Iwasaki Y, Negishi T, Inoue M, Tashiro T, Tabira T, Kimura N (2012) Sendai virus vector-mediated brain-derived neurotrophic factor expression ameliorates memory deficits and synaptic degeneration in a transgenic mouse model of Alzheimer’s disease. J Neurosci Res 90:981–989PubMedGoogle Scholar
  66. Jacobsen JP, Mork A (2004) The effect of escitalopram, desipramine, electroconvulsive seizures and lithium on brain-derived neurotrophic factor mRNA and protein expression in the rat brain and the correlation to 5-HT and 5-HIAA levels. Brain Res 1024:183–192PubMedGoogle Scholar
  67. Katoh-Semba R, Asano T, Ueda H, Morishita R, Takeuchi IK, Inaguma Y, Kato K (2002) Riluzole enhances expression of brain-derived neurotrophic factor with consequent proliferation of granule precursor cells in the rat hippocampus. FASEB 16:1328–1330Google Scholar
  68. Kells AP, Fong DM, Dragunow M, During MJ, Young D, Connor B (2004) AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington disease. Mol Therapy J Am Soc Gene Ther 9:682–688Google Scholar
  69. Koda M, Hashimoto M, Murakami M, Yoshinaga K, Ikeda O, Yamazaki M, Koshizuka S, Kamada T, Moriya H, Shirasawa H, Sakao S, Ino H (2004) Adenovirus vector-mediated in vivo gene transfer of brain-derived neurotrophic factor (BDNF) promotes rubrospinal axonal regeneration and functional recovery after complete transection of the adult rat spinal cord. J Neurotrauma 21:329–337PubMedGoogle Scholar
  70. Kupershmidt L, Weinreb O, Amit T, Mandel S, Carri MT, Youdim MB (2009) Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis. FASEB 23:3766–3779Google Scholar
  71. Kurauchi Y, Hisatsune A, Isohama Y, Mishima S, Katsuki H (2012) Caffeic acid phenethyl ester protects nigral dopaminergic neurons via dual mechanisms involving haem oxygenase-1 and brain-derived neurotrophic factor. Br J Pharmacol 166:1151–1168PubMedCentralPubMedGoogle Scholar
  72. Ladurelle N, Gabriel C, Viggiano A, Mocaer E, Baulieu EE, Bianchi M (2012) Agomelatine (S20098) modulates the expression of cytoskeletal microtubular proteins, synaptic markers and BDNF in the rat hippocampus, amygdala and PFC. Psychopharmacology 221:493–509PubMedGoogle Scholar
  73. Lamballe F, Klein R, Barbacid M (1991) trkC, a new member of the trk family of tyrosine protein kinases, is a receptor for neurotrophin-3. Cell 66:967–979PubMedGoogle Scholar
  74. Lauterbach EC (2012) Psychotropic drug effects on gene transcriptomics relevant to Parkinson’s disease. Prog Neuro-psychopharmacol Biol Psychiatry 38:107–115Google Scholar
  75. Lauterborn JC, Truong GS, Baudry M, Bi X, Lynch G, Gall CM (2003) Chronic elevation of brain-derived neurotrophic factor by ampakines. J Pharmacol Exp Ther 307:297–305PubMedGoogle Scholar
  76. Lauterborn JC, Pineda E, Chen LY, Ramirez EA, Lynch G, Gall CM (2009) Ampakines cause sustained increases in brain-derived neurotrophic factor signaling at excitatory synapses without changes in AMPA receptor subunit expression. Neuroscience 159:283–295PubMedCentralPubMedGoogle Scholar
  77. Lee R, Kermani P, Teng KK, Hempstead BL (2001) Regulation of cell survival by secreted proneurotrophins. Science 294:1945–1948PubMedGoogle Scholar
  78. Lee J, Seroogy KB, Mattson MP (2002) Dietary restriction enhances neurotrophin expression and neurogenesis in the hippocampus of adult mice. J Neurochem 80:539–547PubMedGoogle Scholar
  79. Lee BH, Myint AM, Kim YK (2010) Psychotropic drugs on in vitro brain-derived neurotrophic factor production in whole blood cell cultures from healthy subjects. J Clin Psychopharmacol 30:623–627PubMedGoogle Scholar
  80. Lee MH, Amin ND, Venkatesan A, Wang T, Tyagi R, Pant HC, Nath A (2013) Impaired neurogenesis and neurite outgrowth in an HIV-gp120 transgenic model is reversed by exercise via BDNF production and Cdk5 regulation. J Neurovirol 19:418–431PubMedGoogle Scholar
  81. Levi-Montalcini R (1952) Effects of mouse tumor transplantation on the nervous system. Ann N Y Acad Sci 55:330–344PubMedGoogle Scholar
  82. Levi-Montalcini R, Cohen S (1960) Effects of the extract of the mouse submaxillary salivary glands on the sympathetic system of mammals. Ann N Y Acad Sci 85:324–341PubMedGoogle Scholar
  83. Levi-Montalcini R, Hamburger V (1951) Selective growth stimulating effects of mouse sarcoma on the sensory and sympathetic nervous system of the chick embryo. J Exp Zool 116:321–361PubMedGoogle Scholar
  84. Levivier M, Przedborski S, Bencsics C, Kang UJ (1995) Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson’s disease. J Neurosci Off J Soc Neurosci 15:7810–7820Google Scholar
  85. Leyhe T, Stransky E, Eschweiler GW, Buchkremer G, Laske C (2008) Increase of BDNF serum concentration during donepezil treatment of patients with early Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci 258:124–128PubMedGoogle Scholar
  86. Li Q, Zhao HF, Zhang ZF, Liu ZG, Pei XR, Wang JB, Li Y (2009) Long-term green tea catechin administration prevents spatial learning and memory impairment in senescence-accelerated mouse prone-8 mice by decreasing Abeta1-42 oligomers and upregulating synaptic plasticity-related proteins in the hippocampus. Neuroscience 163:741–749PubMedGoogle Scholar
  87. Lu L, Neff F, Alvarez-Fischer D, Henze C, Xie Y, Oertel WH, Schlegel J, Hartmann A (2005a) Gene expression profiling of Lewy body-bearing neurons in Parkinson’s disease. Exp Neurol 195:27–39PubMedGoogle Scholar
  88. Lu P, Jones LL, Tuszynski MH (2005b) BDNF-expressing marrow stromal cells support extensive axonal growth at sites of spinal cord injury. Exp Neurol 191:344–360PubMedGoogle Scholar
  89. Lu B, Nagappan G, Guan X, Nathan PJ, Wren P (2013) BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. Nat Rev Neurosci 14:401–416PubMedGoogle Scholar
  90. Lynch G, Kramar EA, Rex CS, Jia Y, Chappas D, Gall CM, Simmons DA (2007) Brain-derived neurotrophic factor restores synaptic plasticity in a knock-in mouse model of Huntington’s disease. J Neurosci Off J Soc Neurosci 27:4424–4434Google Scholar
  91. Mackowiak M, O’Neill MJ, Hicks CA, Bleakman D, Skolnick P (2002) An AMPA receptor potentiator modulates hippocampal expression of BDNF: an in vivo study. Neuropharmacology 43:1–10PubMedGoogle Scholar
  92. Maisonpierre PC, Belluscio L, Squinto S, Ip NY, Furth ME, Lindsay RM, Yancopoulos GD (1990) Neurotrophin-3: a neurotrophic factor related to NGF and BDNF. Science 247:1446–1451PubMedGoogle Scholar
  93. Makar TK, Bever CT, Singh IS, Royal W, Sahu SN, Sura TP, Sultana S, Sura KT, Patel N, Dhib-Jalbut S, Trisler D (2009) Brain-derived neurotrophic factor gene delivery in an animal model of multiple sclerosis using bone marrow stem cells as a vehicle. J Neuroimmunol 210:40–51PubMedGoogle Scholar
  94. Mannari C, Origlia N, Scatena A, Del Debbio A, Catena M, Dell’agnello G, Barraco A, Giovannini L, Dell’osso L, Domenici L, Piccinni A (2008) BDNF level in the rat prefrontal cortex increases following chronic but not acute treatment with duloxetine, a dual acting inhibitor of noradrenaline and serotonin re-uptake. Cell Mol Neurobiol 28:457–468PubMedGoogle Scholar
  95. Martinez-Turrillas R, Del Rio J, Frechilla D (2005) Sequential changes in BDNF mRNA expression and synaptic levels of AMPA receptor subunits in rat hippocampus after chronic antidepressant treatment. Neuropharmacology 49:1178–1188PubMedGoogle Scholar
  96. Masliah E, Heaton RK, Marcotte TD, Ellis RJ, Wiley CA, Mallory M, Achim CL, McCutchan JA, Nelson JA, Atkinson JH, Grant I (1997) Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. HNRC Group. The HIV Neurobehavioral Research Center. Ann Neurol 42:963–972PubMedGoogle Scholar
  97. Massa SM, Yang T, Xie Y, Shi J, Bilgen M, Joyce JN, Nehama D, Rajadas J, Longo FM (2010) Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents. J Clin Investig 120:1774–1785PubMedCentralPubMedGoogle Scholar
  98. Matrisciano F, Bonaccorso S, Ricciardi A, Scaccianoce S, Panaccione I, Wang L, Ruberto A, Tatarelli R, Nicoletti F, Girardi P, Shelton RC (2009) Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine. J Psychiatr Res 43:247–254PubMedCentralPubMedGoogle Scholar
  99. Meisner F, Scheller C, Kneitz S, Sopper S, Neuen-Jacob E, Riederer P, ter Meulen V, Koutsilieri E (2008) Memantine upregulates BDNF and prevents dopamine deficits in SIV-infected macaques: a novel pharmacological action of memantine. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 33:2228–2236Google Scholar
  100. Mizuta I, Ohta M, Ohta K, Nishimura M, Mizuta E, Hayashi K, Kuno S (2000) Selegiline and desmethylselegiline stimulate NGF, BDNF, and GDNF synthesis in cultured mouse astrocytes. Biochem Biophys Res Commun 279:751–755PubMedGoogle Scholar
  101. Mocchetti I, Bachis A (2004) Brain-derived neurotrophic factor activation of TrkB protects neurons from HIV-1/gp120-induced cell death. Crit Revi Neurobiol 16:51–57Google Scholar
  102. Molteni R, Calabrese F, Bedogni F, Tongiorgi E, Fumagalli F, Racagni G, Riva MA (2006) Chronic treatment with fluoxetine up-regulates cellular BDNF mRNA expression in rat dopaminergic regions. Int J Neuropsychopharmacol 9:307–317PubMedGoogle Scholar
  103. Nagahara AH, Tuszynski MH (2011) Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Disc 10:209–219Google Scholar
  104. Nagahara AH, Merrill DA, Coppola G, Tsukada S, Schroeder BE, Shaked GM, Wang L, Blesch A, Kim A, Conner JM, Rockenstein E, Chao MV, Koo EH, Geschwind D, Masliah E, Chiba AA, Tuszynski MH (2009) Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer’s disease. Nat Med 15:331–337PubMedCentralPubMedGoogle Scholar
  105. Nath S, Bachani M, Harshavardhana D, Steiner JP (2012) Catechins protect neurons against mitochondrial toxins and HIV proteins via activation of the BDNF pathway. J Neurovirol 18:445–455PubMedGoogle Scholar
  106. Nibuya M, Morinobu S, Duman RS (1995) Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci Off J Soc Neurosci 15:7539–7547Google Scholar
  107. O’Leary PD, Hughes RA (1998) Structure-activity relationships of conformationally constrained peptide analogues of loop 2 of brain-derived neurotrophic factor. J Neurochem 70:1712–1721PubMedGoogle Scholar
  108. O’Leary PD, Hughes RA (2003) Design of potent peptide mimetics of brain-derived neurotrophic factor. J Biol Chem 278:25738–25744PubMedGoogle Scholar
  109. Ochs G, Penn RD, York M, Giess R, Beck M, Tonn J, Haigh J, Malta E, Traub M, Sendtner M, Toyka KV (2000) A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Mot Neuron Disord Off Publ World Fed Neurol Res Group Mot Neuron Dis 1:201–206Google Scholar
  110. Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ (1998) Transport of brain-derived neurotrophic factor across the blood–brain barrier. Neuropharmacology 37:1553–1561PubMedGoogle Scholar
  111. Pardridge WM, Kang YS, Buciak JL (1994) Transport of human recombinant brain-derived neurotrophic factor (BDNF) through the rat blood–brain barrier in vivo using vector-mediated peptide drug delivery. Pharm Res 11:738–746PubMedGoogle Scholar
  112. Park J, Lim E, Back S, Na H, Park Y, Sun K (2010) Nerve regeneration following spinal cord injury using matrix metalloproteinase-sensitive, hyaluronic acid-based biomimetic hydrogel scaffold containing brain-derived neurotrophic factor. J Biomed Mater Res Part A 93:1091–1099Google Scholar
  113. Peng CH, Chiou SH, Chen SJ, Chou YC, Ku HH, Cheng CK, Yen CJ, Tsai TH, Chang YL, Kao CL (2008a) Neuroprotection by Imipramine against lipopolysaccharide-induced apoptosis in hippocampus-derived neural stem cells mediated by activation of BDNF and the MAPK pathway. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol 18:128–140Google Scholar
  114. Peng Q, Masuda N, Jiang M, Li Q, Zhao M, Ross CA, Duan W (2008b) The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington’s disease mouse model. Exp Neurol 210:154–163PubMedCentralPubMedGoogle Scholar
  115. Perez-Navarro E, Canudas AM, Akerund P, Alberch J, Arenas E (2000) Brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4/5 prevent the death of striatal projection neurons in a rodent model of Huntington’s disease. J Neurochem 75:2190–2199PubMedGoogle Scholar
  116. Prior M, Dargusch R, Ehren JL, Chiruta C, Schubert D (2013) The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer’s disease mice. Alzheimer’s Res Ther 5:25Google Scholar
  117. Rahvar M, Nikseresht M, Shafiee SM, Naghibalhossaini F, Rasti M, Panjehshahin MR, Owji AA (2011) Effect of oral resveratrol on the BDNF gene expression in the hippocampus of the rat brain. Neurochem Res 36:761–765PubMedGoogle Scholar
  118. Rasmussen P, Brassard P, Adser H, Pedersen MV, Leick L, Hart E, Secher NH, Pedersen BK, Pilegaard H (2009) Evidence for a release of brain-derived neurotrophic factor from the brain during exercise. Exp Physiol 94:1062–1069PubMedGoogle Scholar
  119. Reichardt LF, Mobley WC (2004) Going the distance, or not, with neurotrophin signals. Cell 118:141–143PubMedGoogle Scholar
  120. Rendeiro C, Vauzour D, Rattray M, Waffo-Teguo P, Merillon JM, Butler LT, Williams CM, Spencer JP (2013) Dietary levels of pure flavonoids improve spatial memory performance and increase hippocampal brain-derived neurotrophic factor. PloS One 8:e63535PubMedCentralPubMedGoogle Scholar
  121. Reus GZ, Abelaira HM, Stringari RB, Fries GR, Kapczinski F, Quevedo J (2012) Memantine treatment reverses anhedonia, normalizes corticosterone levels and increases BDNF levels in the prefrontal cortex induced by chronic mild stress in rats. Metab Brain Dis 27:175–182PubMedGoogle Scholar
  122. Rogoz Z, Legutko B (2005) Combined treatment with imipramine and metyrapone induces hippocampal and cortical brain-derived neurotrophic factor gene expression in rats. Pharmacol Rep 57:840–844PubMedGoogle Scholar
  123. Rogoz Z, Skuza G, Legutko B (2005a) Repeated treatment with mirtazepine induces brain-derived neurotrophic factor gene expression in rats. J Physiol Pharmacol Off J Pol Physiol Soc 56:661–671Google Scholar
  124. Rogoz Z, Budziszewska B, Kubera M, Basta-Kaim A, Jaworska-Feil L, Skuza G, Lason W (2005b) Effect of combined treatment with imipramine and metyrapone on the immobility time, the activity of hypothalamo-pituitary-adrenocortical axis and immunological parameters in the forced swimming test in the rat. J Physiol Pharmacol Off J Pol Physiol Soc 56:49–61Google Scholar
  125. Sakane T, Pardridge WM (1997) Carboxyl-directed pegylation of brain-derived neurotrophic factor markedly reduces systemic clearance with minimal loss of biologic activity. Pharm Res 14:1085–1091PubMedGoogle Scholar
  126. Schabitz WR, Sommer C, Zoder W, Kiessling M, Schwaninger M, Schwab S (2000) Intravenous brain-derived neurotrophic factor reduces infarct size and counterregulates Bax and Bcl-2 expression after temporary focal cerebral ischemia. Stroke J Cereb Circ 31:2212–2217Google Scholar
  127. Soderquist RG, Milligan ED, Sloane EM, Harrison JA, Douvas KK, Potter JM, Hughes TS, Chavez RA, Johnson K, Watkins LR, Mahoney MJ (2009) PEGylation of brain-derived neurotrophic factor for preserved biological activity and enhanced spinal cord distribution. J Biomed Mater Res Part A 91:719–729Google Scholar
  128. Somoza R, Juri C, Baes M, Wyneken U, Rubio FJ (2010) Intranigral transplantation of epigenetically induced BDNF-secreting human mesenchymal stem cells: implications for cell-based therapies in Parkinson’s disease. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 16:1530–1540Google Scholar
  129. Sultana R, Ravagna A, Mohmmad-Abdul H, Calabrese V, Butterfield DA (2005) Ferulic acid ethyl ester protects neurons against amyloid beta- peptide(1–42)-induced oxidative stress and neurotoxicity: relationship to antioxidant activity. J Neurochem 92:749–758PubMedGoogle Scholar
  130. Takeda A, Sakamoto K, Tamano H, Fukura K, Inui N, Suh SW, Won SJ, Yokogoshi H (2011) Facilitated neurogenesis in the developing hippocampus after intake of theanine, an amino acid in tea leaves, and object recognition memory. Cell Mol Neurobiol 31:1079–1088PubMedGoogle Scholar
  131. Takeshima Y, Nakamura M, Miyake H, Tamaki R, Inui T, Horiuchi K, Wajima D, Nakase H (2011) Neuroprotection with intraventricular brain-derived neurotrophic factor in rat venous occlusion model. Neurosurgery 68:1334–1341PubMedGoogle Scholar
  132. Teng HK, Teng KK, Lee R, Wright S, Tevar S, Almeida RD, Kermani P, Torkin R, Chen ZY, Lee FS, Kraemer RT, Nykjaer A, Hempstead BL (2005) ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR and sortilin. J Neurosci Off J Soc Neurosci 25:5455–5463Google Scholar
  133. Torregrossa MM, Isgor C, Folk JE, Rice KC, Watson SJ, Woods JH (2004) The delta-opioid receptor agonist (+)BW373U86 regulates BDNF mRNA expression in rats. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 29:649–659Google Scholar
  134. Visanji NP, Orsi A, Johnston TH, Howson PA, Dixon K, Callizot N, Brotchie JM, Rees DD (2008) PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson’s disease. FASEB 22:2488–2497Google Scholar
  135. Wang ZF, Tang LL, Yan H, Wang YJ, Tang XC (2006) Effects of huperzine A on memory deficits and neurotrophic factors production after transient cerebral ischemia and reperfusion in mice. Pharmacol Biochem Behav 83:603–611PubMedGoogle Scholar
  136. Wang R, Li YB, Li YH, Xu Y, Wu HL, Li XJ (2008) Curcumin protects against glutamate excitotoxicity in rat cerebral cortical neurons by increasing brain-derived neurotrophic factor level and activating TrkB. Brain Res 1210:84–91PubMedGoogle Scholar
  137. Wang Z, Liu Q, Zhang R, Liu S, Xia Z, Hu Y (2009) Catalpol ameliorates beta amyloid-induced degeneration of cholinergic neurons by elevating brain-derived neurotrophic factors. Neuroscience 163:1363–1372PubMedGoogle Scholar
  138. Wu D (2005) Neuroprotection in experimental stroke with targeted neurotrophins. NeuroRx J Am Soc Exp Neurother 2:120–128Google Scholar
  139. Wu A, Ying Z, Gomez-Pinilla F (2006) Dietary curcumin counteracts the outcome of traumatic brain injury on oxidative stress, synaptic plasticity, and cognition. Exp Neurol 197:309–317PubMedGoogle Scholar
  140. Wu H, Lu D, Jiang H, Xiong Y, Qu C, Li B, Mahmood A, Zhou D, Chopp M (2008a) Simvastatin-mediated upregulation of VEGF and BDNF, activation of the PI3K/Akt pathway, and increase of neurogenesis are associated with therapeutic improvement after traumatic brain injury. J Neurotrauma 25:130–139PubMedGoogle Scholar
  141. Wu X, Chen PS, Dallas S, Wilson B, Block ML, Wang CC, Kinyamu H, Lu N, Gao X, Leng Y, Chuang DM, Zhang W, Lu RB, Hong JS (2008b) Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons. Int J Neuropsychopharmacol 11:1123–1134PubMedCentralPubMedGoogle Scholar
  142. Xu H, Steven Richardson J, Li XM (2003) Dose-related effects of chronic antidepressants on neuroprotective proteins BDNF, Bcl-2 and Cu/Zn-SOD in rat hippocampus. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 28:53–62Google Scholar
  143. Yabe T, Hirahara H, Harada N, Ito N, Nagai T, Sanagi T, Yamada H (2010) Ferulic acid induces neural progenitor cell proliferation in vitro and in vivo. Neuroscience 165:515–524PubMedGoogle Scholar
  144. Yagasaki Y, Numakawa T, Kumamaru E, Hayashi T, Su TP, Kunugi H (2006) Chronic antidepressants potentiate via sigma-1 receptors the brain-derived neurotrophic factor-induced signaling for glutamate release. J Biol Chem 281:12941–12949PubMedGoogle Scholar
  145. Yao RQ, Qi DS, Yu HL, Liu J, Yang LH, Wu XX (2012) Quercetin attenuates cell apoptosis in focal cerebral ischemia rat brain via activation of BDNF-TrkB-PI3K/Akt signaling pathway. Neurochem Res 37:2777–2786PubMedGoogle Scholar
  146. Yoshimura R, Kakihara S, Umene-Nakano W, Sugita A, Hori H, Ueda N, Nakamura J (2008) Acute risperidone treatment did not increase daily cigarette consumption or plasma levels of cotinine and caffeine: a pilot study. Hum Psychopharmacol 23:327–332PubMedGoogle Scholar
  147. Youdim MB (2012) M30, a brain permeable multitarget neurorestorative drug in post nigrostriatal dopamine neuron lesion of parkinsonism animal models. Parkinsonism Relat Dis 18(Suppl 1):S151–S154Google Scholar
  148. Youdim MB, Maruyama W, Naoi M (2005) Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline. Drugs Today (Barc) 41:369–391Google Scholar
  149. Young W (2009) Review of lithium effects on brain and blood. Cell Transplant 18:951–975PubMedGoogle Scholar
  150. Zhang F, Lu YF, Wu Q, Liu J, Shi JS (2012a) Resveratrol promotes neurotrophic factor release from astroglia. Exp Biol Med (Maywood) 237:943–948Google Scholar
  151. Zhang F, Wang YY, Liu H, Lu YF, Wu Q, Liu J, Shi JS (2012b) Resveratrol Produces Neurotrophic Effects on Cultured Dopaminergic Neurons through Prompting Astroglial BDNF and GDNF Release. Evid Based Complement Altern Med eCAM 2012:937605Google Scholar
  152. Zhang R, Wang Z, Howson PA, Xia Z, Zhou S, Wu E, Xia Z, Hu Y (2012c) Smilagenin attenuates beta amyloid (25–35)-induced degeneration of neuronal cells via stimulating the gene expression of brain-derived neurotrophic factor. Neuroscience 210:275–285PubMedGoogle Scholar
  153. Zhang Z, Peng D, Zhu H, Wang X (2012d) Experimental evidence of Ginkgo biloba extract EGB as a neuroprotective agent in ischemia stroke rats. Brain Res Bull 87:193–198PubMedGoogle Scholar
  154. Zheng M, Liu C, Pan F, Shi D, Zhang Y (2012) Antidepressant-like effect of hyperoside isolated from Apocynum venetum leaves: possible cellular mechanisms. Phytomed Int J Phytother Phytopharmacol 19:145–149Google Scholar

Copyright information

© Springer Science+Business Media New York (outside the USA) 2014

Authors and Affiliations

  1. 1.NINDS Translational Neuroscience CenterNational Institutes of HealthBethesdaUSA
  2. 2.Section of Infections of the Nervous System, National Institute of Neurological Disorders and StrokeNational Institutes of HealthBethesdaUSA

Personalised recommendations